T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$4.01B |
| 2 |
Broadcom
AVGO
|
+$1.49B |
| 3 |
GE Vernova
GEV
|
+$1.19B |
| 4 |
International Paper
IP
|
+$1.05B |
| 5 |
SCHW
Charles Schwab
SCHW
|
+$952M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2.31B |
| 2 |
Constellation Energy
CEG
|
+$1.94B |
| 3 |
Qualcomm
QCOM
|
+$1.74B |
| 4 |
NVIDIA
NVDA
|
+$1.71B |
| 5 |
Salesforce
CRM
|
+$1.5B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.98% |
| 2 | Healthcare | 14.89% |
| 3 | Financials | 10.35% |
| 4 | Consumer Discretionary | 10.11% |
| 5 | Communication Services | 9.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1126
HEICO Corp Class A
HEI.A
$38.1B
| $8.57M | ﹤0.01% |
48,283
+1,072
| +2% | +$181K |
|
1127
Mohawk Industries
MHK
$9.42B
| $8.43M | ﹤0.01% |
74,219
+464
| +0.6% | +$54K |
|
1128
Oric Pharmaceuticals
ORIC
$1.42B
| $8.41M | ﹤0.01% |
1,189,227
-377,509
| -24% | -$3.38M |
|
1129
Annaly Capital Management
NLY
$17.6B
| $8.23M | ﹤0.01% |
431,884
+6,464
| +2% | +$125K |
|
1130
ArcBest
ARCB
$3.28B
| $8.23M | ﹤0.01% |
76,842
+56,182
| +272% | +$6.77M |
|
1131
Aecom
ACM
$8.19B
| $8.17M | ﹤0.01% |
92,710
+5,409
| +6% | +$493K |
|
1132
NeoGenomics
NEO
$2.11B
| $8.16M | ﹤0.01% |
588,594
-56,898
| -9% | -$807K |
|
1133
Freshworks
FRSH
$3.51B
| $8.16M | ﹤0.01% |
642,637
-388,416
| -38% | -$5.81M |
|
1134
Texas Pacific Land
TPL
$23.9B
| $7.96M | ﹤0.01% |
32,526
-129
| -0.4% | -$27K |
|
1135
AGCO
AGCO
$6.96B
| $7.95M | ﹤0.01% |
81,194
-4,464
| -5% | -$497K |
|
1136
Prime Medicine
PRME
$575M
| $7.95M | ﹤0.01% |
1,545,961
-976,629
| -39% | -$5.92M |
|
1137
Graco
GGG
$13.3B
| $7.93M | ﹤0.01% |
100,041
-87,313
| -47% | -$7.3M |
|
1138
Tarsus Pharmaceuticals
TARS
$3.02B
| $7.92M | ﹤0.01% |
291,275
-56,408
| -16% | -$1.9M |
|
1139
Amdocs
DOX
$6.23B
| $7.85M | ﹤0.01% |
99,421
+51,383
| +107% | +$4.22M |
|
1140
Voyager Therapeutics
VYGR
$198M
| $7.83M | ﹤0.01% |
989,549
-52,381
| -5% | -$439K |
|
1141
Jones Lang LaSalle
JLL
$17B
| $7.7M | ﹤0.01% |
37,481
+60
| +0.2% | +$11.6K |
|
1142
Thryv Holdings
THRY
$96.9M
| $7.62M | ﹤0.01% |
427,408
+3,698
| +0.9% | +$78.5K |
|
1143
Ocular Therapeutix
OCUL
$2.22B
| $7.6M | ﹤0.01% |
1,110,454
+447,782
| +68% | +$2.76M |
|
1144
AnaptysBio
ANAB
$1.66B
| $7.53M | ﹤0.01% |
300,224
+128,535
| +75% | +$2.99M |
|
1145
Rithm Capital
RITM
$5.79B
| $7.52M | ﹤0.01% |
689,390
+463,488
| +205% | +$5.13M |
|
1146
Twilio
TWLO
$38.3B
| $7.27M | ﹤0.01% |
127,940
+4,837
| +4% | +$285K |
|
1147
NorthWestern Energy
NWE
$4.4B
| $7.26M | ﹤0.01% |
144,955
+30,288
| +26% | +$1.53M |
|
1148
Spyre Therapeutics
SYRE
$8.98B
| $7.24M | ﹤0.01% |
307,976
+229,447
| +292% | +$7.74M |
|
1149
Old Republic International
ORI
$10.3B
| $7.21M | ﹤0.01% |
233,232
+17,002
| +8% | +$521K |
|
1150
Valmont Industries
VMI
$9.5B
| $7.2M | ﹤0.01% |
26,240
-689
| -3% | -$168K |
|
Similar funds
T. Rowe Price Associates's Q2 2024 Portfolio in Review
As of Q2 2024, T. Rowe Price Associates held 3,089 positions worth $836B, up 2.4% from $816B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
T. Rowe Price Associates's Q2 2024 filing shows 135 new, 1,850 increased, 836 reduced and 113 closed positions. Its largest new stake was Tempus AI: 5,227,120 shares worth $183M. The largest sale was Microsoft, an estimated $2.31B.
By sector, the portfolio is most concentrated in Technology at 34% of assets, up from 32% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2024 buy was Tempus AI: 5,227,120 shares worth $183M.
- T. Rowe Price Associates added most to Apple in Q2 2024, an estimated $4.01B increase.
- T. Rowe Price Associates's biggest Q2 2024 reduction was Microsoft, cutting an estimated $2.31B.
- T. Rowe Price Associates fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $570M.
- T. Rowe Price Associates's ten largest holdings make up 36% of its $836B portfolio in Q2 2024.
- T. Rowe Price Associates opened 135 new positions and closed 113 in Q2 2024.
- T. Rowe Price Associates's portfolio value rose 2.4% quarter-over-quarter to $836B.
Based on T. Rowe Price Associates's 13F filing for Q2 2024, filed 14 Aug 2024.